Bevacizumab Market Research Report – Segmentation by Product Type (Branded Products, Biosimilars); By Application (Indication) (Oncology, Ophthalmology, Others); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies); By End User (Hospitals, Clinics, Research Institutes); and Region - Size, Share, Growth Analysis | Forecast (2025– 2030)

Bevacizumab Market Size (2025-2030)

The Bevacizumab Market was valued at $6.78 billion and is projected to reach a market size of $8.91 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 5.6%. 

The Bevacizumab market is witnessing significant growth due to the growing cancer prevalence and development of biosimilars. The North American market contributes a major market share due to well-developed medical infrastructure and high cancer incidence rates. In 2024, the US region alone registered about 1.9 million new cancer diagnoses and 693,000 deaths related to cancer. Europe also has a high market share, led by regulatory approvals and biosimilar uptake, while the Asia-Pacific region is expected to experience strong growth due to growing healthcare spending and an expanding patient base. The market's growth is generally fueled by the need for affordable cancer treatments and continued product development innovations.

Key Market Insights:

• The biosimilars category is growing aggressively and is expected to hit $1.55 billion in 2025 and $2.09 billion by 2030 at a CAGR of 6.16%. Product development innovations are seen, such as the introduction of Abevmy, a Health Canada-approved biosimilar for four oncology indications.
• Strategic partnerships are transforming the industry landscape; significantly, Prestige Biopharma collaborated with Intas Pharmaceuticals in May 2022 to market the bevacizumab biosimilar HD204 in major regions, including the U.S. and Europe.
• Furthermore, Biocon Biologics Ltd. purchased Viatris Inc.'s global biosimilars business in November 2022 with a view to solidifying its market position in the biosimilars industry. These events highlight an active market driven by strategic partnerships and innovative product launches.

Bevacizumab Market Key Drivers:

Rising Cancer Incidence Driving Demand for Bevacizumab Treatments

• Growing Prevalence of Cancer: The growing prevalence of several cancers, such as such as colorectal, lung, breast, and kidney cancers, has increased the need for suitable treatments such as Bevacizumab. Bevacizumab is a monoclonal antibody that blocks angiogenesis, thus preventing tumor growth.
   
• Regulatory Approvals and Product Launches: Recent product approvals and launches and launches Bevacizumab biosimilars have opened treatment alternatives and enhanced market accessibility. For example, in December 2023, Bio-Thera Solutions' Avastin biosimilar bevacizumab-tnjn (Avzivi) was approved by the U.S. FDA to treat lung and colorectal cancer.
• Advances in Biotechnology and Research: Advances in biotechnology have resulted in

the creation of more efficient and targeted cancer drugs, improving the effectiveness of drugs such as Bevacizumab. Such advances are factors in the growth of the drug’s adoption and market.

Bevacizumab Market Restraints and Challenges:

The Bevacizumab market is beset by several key challenges and limitations that affect its growth trend. One such problem is the recent supply chain disruption; for example, Pine Pharmaceuticals, which is a primary supplier of repackaged Avastin (Bevacizumab), halted production in October 2024, which caused retina specialists to struggle to access the drug and potentially create delays in treatments for patients suffering from diseases such as age-related macular degeneration. In addition, the expensive price of Bevacizumab creates a hurdle towards universal usage, especially in developing countries. The cost of a year's treatment can be over $100,000, placing economic burdens on patients and health systems. Also, though biosimilars' introduction helps in cutting down expenses and improving access, their launch into the market is generally slowed by regulatory obstacles, mainly with respect to production processes and facility regulation. These delays can prevent timely access to cheaper treatment alternatives. Finally, safety issues related to Bevacizumab, including hypertension, bleeding, and thrombotic events, require careful monitoring. These side effects can restrict its use in some patient groups, thus limiting market growth.

Bevacizumab Market Opportunities:

The Subscription and Billing Management industry is expected to witness considerable growth, spurred by several emerging opportunities. The growth in the use of subscription business models in numerous industries requires sophisticated billing solutions for handling intricate pricing schemes and revenue recognition. With companies shifting from legacy sales to recurring revenues, the need for advanced subscription and billing management systems grows. The emergence of digital transformation programs further fuels this demand. Organizations are coming to rely on cloud-based offerings due to their scalability and adaptability, so they can handle subscription-based offerings efficiently. Further, the heightened focus on retaining customers and giving them a tailored experience opens opportunities for subscription and billing management platforms to increase satisfaction levels and churn rates. Businesses can encourage loyalty and keep competition at bay by offering customized price plans, offers, and promotions.

BEVACIZUMAB MARKET REPORT COVERAGE:

Bevacizumab Market Segmentation:

Bevacizumab Market Segmentation By Product Type:

• Branded Products
• Biosimilars

While there is a long history of branded products leading the market, biosimilars are gaining ground. In America, biosimilars attained a patient share of more than 60% by 2024, and it is estimated that they will hold a share of the bevacizumab market equal to about 75% by the year 2030. This can be attributed to the cost benefits associated with biosimilars and their growing popularity in clinical practice

Bevacizumab Market Segmentation By Application (Indication):

• Oncology
• Ophthalmology
• Others

Of these, the oncology segment leads, mainly because of Bevacizumab's success in treating cancers like colorectal, lung, breast, and renal cell carcinoma. Its action of blocking angiogenesis, which is critical for tumor growth, has cemented its position in oncology treatment regimens. The increasing incidence of cancer worldwide further drives demand in this segment. On the other hand, the ophthalmology sector, for which Bevacizumab is being used off-label to cure diseases such as age-related macular degeneration and diabetic retinopathy, is growing at a phenomenal rate. This growth is related to an aging population and growing cases of diabetes, resulting in more cases of retinal illnesses. Thus, while oncology is the biggest market usage, the ophthalmology sector is the fastest growing one in the Bevacizumab market.

Bevacizumab Market Segmentation By Distribution Channel;

• Hospital Pharmacies
• Retail Pharmacies and Drug Stores
• Online Pharmacies

Hospital pharmacies lead the distribution channels in the Bevacizumab market today due to the specialized nature of cancer care requiring administration within hospital environments that have the necessary medical infrastructure. Yet, online pharmacies are proving to be the fastest-growing channel, facilitated by the rising use of digital healthcare solutions and the convenience of home delivery options. The growth of online e-commerce sites and improvements in logistics have enabled patients to access their drugs more conveniently online, fueling the fast growth of this channel.

Bevacizumab Market Segmentation By End User:

• Hospitals
• Clinics
• Research Institutes

Hospitals are the leading end-users in the Bevacizumab market, mainly because of the sophisticated nature of cancer therapy that requires specialized medical facilities and multidisciplinary medical teams provided within the hospital environment. This leadership is further supported by the intense need for Bevacizumab in oncology therapy, since the administration of advanced therapies is mainly provided within the primary centers operated by hospitals. Specialized oncology and ophthalmology clinics also play an important part, providing target therapies and patient-specific management. The convenience of and specialized service offered by the clinics account for their large portion in the market. Research institutions, as important as they are for driving clinical use and investigating new bevacizumab therapeutic uses, account for a smaller sector in terms of actual drug consumption. Their core focus is to perform clinical trials and translational research, thereby indirectly facilitating market expansion through widening the potential use of the drug.

Bevacizumab Market Regional Analysis:

The Bevacizumab market has characteristic regional trends with North America heading the market in light of established healthcare infrastructure and favorable regulatory environment. Europe stands next, given established biosimilar approval systems, followed by Asia-Pacific growing faster with growing instances of cancer cases and investments into healthcare. The Middle East & Africa and Latin America presently retain smaller shares in the market but offer promise to grow further in the future when healthcare infrastructures mature and more biosimilars are being adopted.

COVID-19 Impact Analysis on the Bevacizumab Market:

The COVID-19 pandemic influenced the Bevacizumab market in a variety of ways. On the one hand, the sales of Bevacizumab witnessed a significant rise, as shown by Amgen Inc.'s MVASI (Bevacizumab) U.S. sales, which jumped from USD 121 million in 2019 to USD 656 million in 2020. Outside the U.S., sales increased from USD 6 million in 2019 to USD 142 million in 2020. This rise can be linked to the efficacy of the drug in cancer therapy and its prospect in treating COVID-19-associated complications, including acute lung injury and acute respiratory distress syndrome. On the other hand, the pandemic resulted in a sharp decrease in intravitreal injections (IVI) of Bevacizumab for ophthalmic purposes. It was reported in a study conducted at Shaare Zedek Medical Center in Israel that there was a 44% drop in Bevacizumab IVIs from March 15 to April 14, 2020, from the corresponding period in 2019, mainly because patients were avoiding visits to healthcare centers during the fear of infection.

Recent Trends/Developments:

The Bevacizumab market has witnessed significant developments in the last few years, led notably by the introduction and regulatory approvals of biosimilars. In December 2023, the US FDA approved Bio-Thera Solutions' Avzivi (bevacizumab-tnjn), becoming the fifth bevacizumab biosimilar to be approved for the treatment of different types of cancers. The approval testifies to increased recognition and assimilation of biosimilars within oncology therapeutic regimens. Joint ventures have also defined the market scenario; for example, in July 2022, Prestige Biopharma Limited entered a collaboration with Intas Pharmaceuticals Limited to exclusively market Prestige's bevacizumab biosimilar in several countries to improve global access to affordable cancer treatments. In addition, market forecasts point to strong growth, with the global bevacizumab biosimilars market set to grow at a compound annual growth rate (CAGR) of 5.6%. This expansion is fueled by trends like the rising incidence of cancer and the need for affordable biologic drugs. Taken together, these trends reflect a dynamic market landscape, marked by regulatory innovation, strategic partnerships, and a commitment to increasing patient access to critical oncology drugs

Key Players in the Bevacizumab Market:

1. Genentech, Inc. (a member of the Roche Group)
2. Amgen Inc.
3. Pfizer Inc.
4. Mylan N.V.
5. Samsung Bioepis
6. Celltrion Healthcare Co., Ltd.
7. Prestige Biopharma
8. Fujifilm Kyowa Kirin Biologics
9. AryoGen Pharmed
10. Zydus Cadila